Literature DB >> 18648740

Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs).

Shigeharu Miwa1, Takahiko Nakajima, Yoshihiro Murai, Yasuo Takano, Toshiro Sugiyama.   

Abstract

BACKGROUND: Recently, the novel gene DOG1 has been found to be overexpressed in most gastrointestinal stromal tumors (GISTs) specifically within the field of soft tissue tumors. DOG1 might play a role in development of GISTs and have potential as a diagnostic marker and therapeutic target, but the biological function and the overexpression mechanism have not yet been investigated. In this study we examined whether the DOG1 gene mutation occurs as with the KIT gene and PDGFRA gene.
METHODS: We investigated ten resected primary GIST tissues. All cases were examined for immunoreactivity for KIT and DOG1 and screened for mutation in the KIT gene (exons 9, 11, 13, and 17) and the PDGFRA gene (exons 12, 14, and 18) by direct DNA sequencing. Four cases with relatively good quality DNA were analyzed for the DOG1 gene (exons 1-26) mutation.
RESULTS: All ten GISTs showed immunoreactivity for KIT. Although all cases expressed DOG1 in immunohistochemistry, we could not find any mutations within all 26 exons (a total of 104 exons) of the DOG1 gene in the four analyzed cases.
CONCLUSIONS: Based on four cases, the DOG1 gene was found not to be mutated in GISTs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18648740     DOI: 10.1007/s00535-008-2195-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  21 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital.

Authors:  Tokimasa Kumada; Koichi Tsuneyama; Hideki Hatta; Shin Ishizawa; Yasuo Takano
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

3.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

Authors:  Christopher L Corless; Laura McGreevey; Andrea Haley; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours.

Authors:  H Chen; S Hirota; K Isozaki; H Sun; A Ohashi; K Kinoshita; P O'Brien; L Kapusta; I Dardick; T Obayashi; T Okazaki; Y Shinomura; Y Matsuzawa; Y Kitamura
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

5.  A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Authors:  Lei L Chen; Jonathan C Trent; Elsie F Wu; Gregory N Fuller; Latha Ramdas; Wei Zhang; Austin K Raymond; Victor G Prieto; Caroline O Oyedeji; Kelly K Hunt; Raphael E Pollock; Barry W Feig; Kimberly J Hayes; Haesun Choi; Homer A Macapinlac; Walter Hittelman; Marco A Velasco; Shreyaskumar Patel; Michael A Burgess; Robert S Benjamin; Marsha L Frazier
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

6.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

7.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

8.  A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.

Authors:  Akira Sawaki; Kenji Yamao; Tsuneya Nakamura; Takashi Suzuki; Kenji Okubo; Kazuo Hara; Hiroki Kawai; Yoshitaka Yamamura; Seiji Ito; Yoshinari Mochiduki; Ryuzo Ohno
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

Review 9.  Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors.

Authors:  Yasuhisa Shinomura; Kazuo Kinoshita; Shusaku Tsutsui; Seiichi Hirota
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 6.772

10.  Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.

Authors:  T Wakai; T Kanda; S Hirota; A Ohashi; Y Shirai; K Hatakeyama
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

View more
  9 in total

1.  Presence of PDGFRA and DOG1 mutations in gastrointestinal stromal tumors among Chinese population.

Authors:  Jiehua Li; Haitian Zhang; Yunfei Lu; Zhibai Chen; Ka Su
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Perineurioma in the sigmoid colon diagnosed and treated by endoscopic resection.

Authors:  Yasuteru Fujino; Naoki Muguruma; Shinji Kitamura; Yasuhiro Mitsui; Tetsuo Kimura; Hiroshi Miyamoto; Hisanori Uehara; Koichi Kataoka; Tetsuji Takayama
Journal:  Clin J Gastroenterol       Date:  2014-08-19

3.  Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis.

Authors:  Beril Güler; Filiz Özyılmaz; Burcu Tokuç; Nuray Can; Ebru Taştekin
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

Review 4.  Chloride channels: often enigmatic, rarely predictable.

Authors:  Charity Duran; Christopher H Thompson; Qinghuan Xiao; H Criss Hartzell
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 5.  Anoctamin/TMEM16 family members are Ca2+-activated Cl- channels.

Authors:  H Criss Hartzell; Kuai Yu; Qinhuan Xiao; Li-Ting Chien; Zhiqiang Qu
Journal:  J Physiol       Date:  2008-11-17       Impact factor: 5.182

6.  DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

Authors:  Susanne Simon; Florian Grabellus; Loretta Ferrera; Luis Galietta; Benjamin Schwindenhammer; Thomas Mühlenberg; Georg Taeger; Grant Eilers; Juergen Treckmann; Frank Breitenbuecher; Martin Schuler; Takahiro Taguchi; Jonathan A Fletcher; Sebastian Bauer
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

7.  Therapeutic effect and mechanism of electroacupuncture at Zusanli on plasticity of interstitial cells of Cajal: a study of rat ileum.

Authors:  Mei-fang Peng; Kun Li; Chao Wang; Xiao-yan Zhu; Zheng Yang; Guo-hu Zhang; Pei-hong Wang; Yong-hua Wang; Li-jun Tang; Lin Zhang
Journal:  BMC Complement Altern Med       Date:  2014-06-07       Impact factor: 3.659

8.  Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours - an analysis of 70 cases from 2004 to 2010.

Authors:  Joanna Kiśluk; Justyna Zińczuk; Andrzej Kemona; Katarzyna Guzińska-Ustymowicz; Joanna Żurawska; Bogusław Kędra
Journal:  Prz Gastroenterol       Date:  2015-06-24

9.  Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Authors:  David S Moura; Rafael Ramos; Antonio Fernandez-Serra; Teresa Serrano; Julia Cruz; Ramiro Alvarez-Alegret; Rosa Ortiz-Duran; Luis Vicioso; Maria Luisa Gomez-Dorronsoro; Xavier Garcia Del Muro; Javier Martinez-Trufero; Jordi Rubio-Casadevall; Isabel Sevilla; Nuria Lainez; Antonio Gutierrez; Cesar Serrano; Maria Lopez-Alvarez; Nadia Hindi; Miguel Taron; José Antonio López-Guerrero; Javier Martin-Broto
Journal:  Oncotarget       Date:  2018-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.